Physician profile
Stephen Tai
NPI 1689870073
$5,754.82
in general payments reported to CMS, 2019-2025
35 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 89% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $536 · 2021: $411 · 2022: $348 · 2023: $942 · 2024: $882 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Travel and Lodging: $681 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.03 |
| Travel and Lodging | $680.89 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,315.27 | 2019-2025 | |
| Stryker Corporation | $906.13 | 2019-2025 | Scopis Ent, Clarifix, Nasopore |
| Glaxosmithkline, LLC. | $773.74 | 2021-2025 | Nucala |
| Optinose US, INC. | $373.99 | 2019-2025 | |
| Alk-Abello, INC | $279.45 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $237.50 | 2019-2025 | Dupixent |
| Cochlear Americas | $211.89 | 2019-2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Sanofi-Aventis U.S. LLC | $184.20 | 2021-2025 | |
| Kaleo, INC. | $160.11 | 2019-2022 | |
| Medtronic USA, INC. | $150.00 | 2020 | |
| Hologic Sales and Service, LLC | $145.43 | 2025 | Coolseal Generator |
| Jazz Pharmaceuticals INC. | $132.77 | 2019-2021 | |
| Inspire Medical Systems, INC. | $99.13 | 2023-2025 | Inspire |
| Aerin Medical INC. | $98.83 | 2020-2025 | |
| Smith+Nephew, INC. | $67.41 | 2021-2025 | Tula |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $65.59 | 2019-2023 | Acclarent Aera, Relieva Spinplus |
| Intersect Ent, INC. | $54.67 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $53.45 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $51.33 | 2023-2024 | Lumryz |
| Medtronic, INC. | $43.11 | 2023-2025 | Propel |
| Karl Storz Endoscopy-America | $32.34 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.16 | 2020 | |
| Phadia US INC. | $32.02 | 2021-2025 | Immunocap |
| Quidel Corporation | $31.76 | 2019 | |
| Acera Surgical, INC. | $30.00 | 2025 | Restrata Wound Matrix |
| Greer Laboratories, INC. | $29.67 | 2019 | |
| Merck Sharp & Dohme LLC | $29.22 | 2021-2023 | |
| Xoran Technologies LLC | $24.98 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $19.30 | 2025 | Neffy |
| Resmed Corp | $18.05 | 2019 | |
| Lilly USA, LLC | $17.10 | 2025 | Zepbound |
| Olympus America INC. | $16.28 | 2019 | |
| Paratek Pharmaceuticals, INC. | $15.21 | 2025 | Xhance |
| Novartis Pharmaceuticals Corporation | $11.73 | 2019 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Tai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.